{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T13:51:07Z","timestamp":1768917067937,"version":"3.49.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,11,20]],"date-time":"2021-11-20T00:00:00Z","timestamp":1637366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,11,20]],"date-time":"2021-11-20T00:00:00Z","timestamp":1637366400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1007\/s00415-021-10910-1","type":"journal-article","created":{"date-parts":[[2021,11,20]],"date-time":"2021-11-20T07:04:33Z","timestamp":1637391873000},"page":"1678-1687","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Progressive multifocal leukoencephalopathy and sphingosine 1-phosphate receptor modulators used in multiple sclerosis: an updated review of literature"],"prefix":"10.1007","volume":"269","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6844-3287","authenticated-orcid":false,"given":"Shitiz","family":"Sriwastava","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Durgesh","family":"Chaudhary","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samiksha","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine","family":"Beard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xue","family":"Bai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sijin","family":"Wen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Syed Hassan","family":"Khalid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert P.","family":"Lisak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,11,20]]},"reference":[{"issue":"16","key":"10910_CR1","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1007\/s40265-017-0814-1","volume":"77","author":"G Comi","year":"2017","unstructured":"Comi G, Hartung HP, Bakshi R, Williams IM, Wiendl H (2017) Benefit-risk profile of Sphingosine-1-Phosphate receptor modulators in relapsing and secondary progressive multiple sclerosis. Drugs 77(16):1755\u20131768. https:\/\/doi.org\/10.1007\/s40265-017-0814-1 (PMID: 28905255; PMCID: PMC5661009)","journal-title":"Drugs"},{"issue":"4","key":"10910_CR2","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1007\/s13311-017-0565-4","volume":"14","author":"BZ Chaudhry","year":"2017","unstructured":"Chaudhry BZ, Cohen JA, Conway DS (2017) Sphingosine 1-Phosphate receptor modulators for the treatment of multiple sclerosis. Neurotherapeutics 14(4):859\u2013873. https:\/\/doi.org\/10.1007\/s13311-017-0565-4 (PMID: 28812220; PMCID: PMC5722770)","journal-title":"Neurotherapeutics"},{"issue":"7","key":"10910_CR3","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s40263-015-0261-z","volume":"29","author":"AM Subei","year":"2015","unstructured":"Subei AM, Cohen JA (2015) Sphingosine 1-phosphate receptor modulators in multiple sclerosis. CNS Drugs 29(7):565\u2013575. https:\/\/doi.org\/10.1007\/s40263-015-0261-z (PMID: 26239599; PMCID: PMC4554772)","journal-title":"CNS Drugs"},{"issue":"1","key":"10910_CR4","doi-asserted-by":"publisher","first-page":"49","DOI":"10.4103\/0976-500X.77118","volume":"2","author":"S Sharma","year":"2011","unstructured":"Sharma S, Mathur AG, Pradhan S, Singh DB, Gupta S (2011) Fingolimod (FTY720): first approved oral therapy for multiple sclerosis. J Pharmacol Pharmacother 2(1):49","journal-title":"J Pharmacol Pharmacother"},{"issue":"9","key":"10910_CR5","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1007\/s40265-019-01140-x","volume":"79","author":"ZT Al-Salama","year":"2019","unstructured":"Al-Salama ZT (2019) Siponimod: first global approval. Drugs 79(9):1009\u20131015","journal-title":"Drugs"},{"key":"10910_CR6","doi-asserted-by":"crossref","unstructured":"Lamb YN (2020) Ozanimod: first approval. Drugs 80(8):841\u2013848. Drug Trials Snapshots: ZEPOSIA | FDA. https:\/\/www.fda.gov\/drugs\/development-approval-process-drugs\/drug-trials-snapshots-zeposia. Accessed 23 Aug 2021","DOI":"10.1007\/s40265-020-01319-7"},{"key":"10910_CR7","unstructured":"Janssen Announces U.S. (2021) FDA Approval of PONVORYTM (ponesimod), an Oral Treatment for Adults with Relapsing Multiple Sclerosis Proven Superior to Aubagio\u00ae (teriflunomide) in Reducing Annual Relapses and Brain Lesions | Janssen. https:\/\/www.janssen.com\/janssen-announces-us-fda-approval-ponvory-ponesimod-oral-treatment-adults-relapsing-multiple. Accessed 23 Aug 2021"},{"issue":"6","key":"10910_CR8","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/S1474-4422(14)70049-3","volume":"13","author":"PA Calabresi","year":"2014","unstructured":"Calabresi PA, Radue EW, Goodin D, Jeffery D, Rammohan KW, Reder AT, Vollmer T, Agius MA, Kappos L, Stites T, Li B, Cappiello L, von Rosenstiel P, Lublin FD (2014) Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol 13(6):545\u2013556. https:\/\/doi.org\/10.1016\/S1474-4422(14)70049-3 (Epub 2014 Mar 28. Erratum in: Lancet Neurol. 2013 Jun;13(6):536. PMID: 24685276)","journal-title":"Lancet Neurol"},{"issue":"5","key":"10910_CR9","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1056\/NEJMoa0907839","volume":"362","author":"JA Cohen","year":"2010","unstructured":"Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, Pelletier J, Capra R, Gallo P, Izquierdo G, Tiel-Wilck K, de Vera A, Jin J, Stites T, Wu S, Aradhye S, Kappos L, TRANSFORMS Study Group (2010) Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 362(5):402\u2013415. https:\/\/doi.org\/10.1056\/NEJMoa0907839 (Epub 2010 Jan 20. PMID: 20089954)","journal-title":"N Engl J Med"},{"issue":"11","key":"10910_CR10","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/S1474-4422(19)30239-X","volume":"18","author":"G Comi","year":"2019","unstructured":"Comi G, Kappos L, Selmaj KW, Bar-Or A, Arnold DL, Steinman L, Hartung HP, Montalban X, Kubala Havrdov\u00e1 E, Cree BAC, Sheffield JK, Minton N, Raghupathi K, Ding N, Cohen JA, SUNBEAM Study Investigators (2019) Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial. Lancet Neurol 18(11):1009\u20131020. https:\/\/doi.org\/10.1016\/S1474-4422(19)30239-X (Epub 2019 Sep 3. PMID: 31492651)","journal-title":"Lancet Neurol"},{"issue":"11","key":"10910_CR11","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/S1474-4422(19)30238-8","volume":"18","author":"JA Cohen","year":"2019","unstructured":"Cohen JA, Comi G, Selmaj KW, Bar-Or A, Arnold DL, Steinman L, Hartung HP, Montalban X, Kubala Havrdov\u00e1 E, Cree BAC, Sheffield JK, Minton N, Raghupathi K, Huang V, Kappos L, RADIANCE Trial Investigators (2019) Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial. Lancet Neurol 18(11):1021\u20131033. https:\/\/doi.org\/10.1016\/S1474-4422(19)30238-8 (Epub 2019 Sep 3 PMID: 31492652)","journal-title":"Lancet Neurol"},{"issue":"1","key":"10910_CR12","first-page":"2","volume":"1","author":"KW Selmaj","year":"2019","unstructured":"Selmaj KW, Steinman L, Comi G, Bar-Or A, Arnold DL, Hartung HP, Montalban X, Havrdov\u00e1 EK, Sheffield JK, Liu H, Minton N (2019) Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: results from the DAYBREAK open-label extension study. Mult Scler 1(1):2","journal-title":"Mult Scler"},{"issue":"4","key":"10910_CR13","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S1474-4422(10)70040-5","volume":"9","author":"CS Tan","year":"2010","unstructured":"Tan CS, Koralnik IJ (2010) Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis. Lancet Neurol 9(4):425\u2013437. https:\/\/doi.org\/10.1016\/S1474-4422(10)70040-5 (PMID: 20298966; PMCID: PMC2880524)","journal-title":"Lancet Neurol"},{"issue":"11","key":"10910_CR14","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1056\/NEJMoa0810316","volume":"361","author":"H Lind\u00e5","year":"2009","unstructured":"Lind\u00e5 H, von Heijne A, Major EO, Ryschkewitsch C, Berg J, Olsson T, Martin C (2009) Progressive multifocal leukoencephalopathy after natalizumab monotherapy. N Engl J Med 361(11):1081\u20131087. https:\/\/doi.org\/10.1056\/NEJMoa0810316 (PMID: 19741229)","journal-title":"N Engl J Med"},{"issue":"10","key":"10910_CR15","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1002\/acn3.114","volume":"1","author":"T Dong-Si","year":"2014","unstructured":"Dong-Si T, Richman S, Wattjes MP, Wenten M, Gheuens S, Philip J, Datta S, McIninch J, Bozic C, Bloomgren G, Richert N (2014) Outcome and survival of asymptomatic PML in natalizumab-treated MS patients. Ann Clin Transl Neurol 1(10):755\u2013764. https:\/\/doi.org\/10.1002\/acn3.114 (Epub 2014 Oct 9. PMID: 25493267; PMCID: PMC4241803)","journal-title":"Ann Clin Transl Neurol"},{"issue":"5","key":"10910_CR16","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000274","volume":"3","author":"M Baharnoori","year":"2016","unstructured":"Baharnoori M, Lyons J, Dastagir A, Koralnik I, Stankiewicz JM (2016) Nonfatal PML in a patient with multiple sclerosis treated with dimethyl fumarate. Neurol Neuroimmunol Neuroinflamm 3(5):e274. https:\/\/doi.org\/10.1212\/NXI.0000000000000274 (PMID: 27606353; PMCID: PMC4996537)","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10910_CR17","doi-asserted-by":"publisher","first-page":"135245852094915","DOI":"10.1177\/1352458520949158","volume":"18","author":"AL Jordan","year":"2020","unstructured":"Jordan AL, Yang J, Fisher CJ, Racke MK, Mao-Draayer Y (2020) Progressive multifocal leukoencephalopathy in dimethyl fumarate-treated multiple sclerosis patients. Mult Scler 18:1352458520949158. https:\/\/doi.org\/10.1177\/1352458520949158 (Epub ahead of print. PMID: 32808554; PMCID: PMC7889744)","journal-title":"Mult Scler"},{"issue":"20","key":"10910_CR18","doi-asserted-by":"publisher","first-page":"e1815","DOI":"10.1212\/WNL.0000000000005529","volume":"90","author":"JR Berger","year":"2018","unstructured":"Berger JR, Cree BA, Greenberg B, Hemmer B, Ward BJ, Dong VM, Merschhemke M (2018) Progressive multifocal leukoencephalopathy after fingolimod treatment. Neurology 90(20):e1815\u2013e1821. https:\/\/doi.org\/10.1212\/WNL.0000000000005529 (Epub 2018 Apr 18. PMID: 29669908; PMCID: PMC5957303)","journal-title":"Neurology"},{"issue":"6","key":"10910_CR19","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1001\/jamaneurol.2021.0627","volume":"78","author":"A Patel","year":"2021","unstructured":"Patel A, Sul J, Gordon ML, Steinklein J, Sanguinetti S, Pramanik B, Purohit D, Haroutunian V, Williamson A, Koralnik I, Harel A (2021) Progressive multifocal leukoencephalopathy in a patient with progressive multiple sclerosis treated with ocrelizumab monotherapy. JAMA Neurol 78(6):736\u2013740. https:\/\/doi.org\/10.1001\/jamaneurol.2021.0627 (PMID: 33724354; PMCID: PMC7967248)","journal-title":"JAMA Neurol"},{"issue":"8","key":"10910_CR20","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1177\/1352458519832259","volume":"25","author":"S Gerevini","year":"2019","unstructured":"Gerevini S, Capra R, Bertoli D, Sottini A, Imberti L (2019) Immune profiling of a patient with alemtuzumab-associated progressive multifocal leukoencephalopathy. Mult Scler 25(8):1196\u20131201. https:\/\/doi.org\/10.1177\/1352458519832259 (Epub 2019 Apr 9 PMID: 30964396)","journal-title":"Mult Scler"},{"key":"10910_CR21","unstructured":"OZA009 [Data on file]. Bristol-Myers Squibb. 2021, Drug Trials Snapshots: ZEPOSIA | FDA. https:\/\/www.fda.gov\/drugs\/development-approval-process-drugs\/drug-trials-snapshots-zeposia. Accessed 23 Aug 2021"},{"issue":"5","key":"10910_CR22","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1001\/archneurol.2009.31","volume":"66","author":"A Boster","year":"2009","unstructured":"Boster A, Hreha S, Berger JR, Bao F, Penmesta R, Tselis A, Endress C, Zak I, Perumal J, Caon C, Vazquez J, Tyler KL, Racke MK, Millis S, Khan O (2009) Progressive multifocal leukoencephalopathy and relapsing-remitting multiple sclerosis: a comparative study. Arch Neurol 66(5):593\u2013599. https:\/\/doi.org\/10.1001\/archneurol.2009.31 (PMID: 19433659)","journal-title":"Arch Neurol"},{"key":"10910_CR23","unstructured":"Fox R, Cree B, Greenberg B, Hemmer B, Ward BJ, Ontaneda D, Moore A, Zhang Y, Sullivan R, Girase P, Hach T (2020) Update on the risk estimates of progressive multifocal leukoencephalopathy related to fingolimod. MSVirtual"},{"issue":"7","key":"10910_CR24","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6(7):e1000097. https:\/\/doi.org\/10.1371\/journal.pmed.1000097 (Epub 2009 Jul 21. PMID: 19621072; PMCID: PMC2707599)","journal-title":"PLoS Med"},{"issue":"5","key":"10910_CR25","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1136\/practneurol-2015-001355","volume":"16","author":"G Giovannoni","year":"2016","unstructured":"Giovannoni G, Marta M, Davis A, Turner B, Gnanapavan S, Schmierer K (2016) Switching patients at high risk of PML from natalizumab to another disease-modifying therapy. Pract Neurol 16(5):389\u2013393. https:\/\/doi.org\/10.1136\/practneurol-2015-001355 (Epub 2016 Apr 25 PMID: 27114560)","journal-title":"Pract Neurol"},{"key":"10910_CR26","doi-asserted-by":"publisher","first-page":"307872","DOI":"10.1155\/2014\/307872","volume":"2014","author":"J Killestein","year":"2014","unstructured":"Killestein J, Vennegoor A, van Golde AE, Bourez RL, Wijlens ML, Wattjes MP (2014) PML-IRIS during fingolimod diagnosed after natalizumab discontinuation. Case Rep Neurol Med. 2014:307872. https:\/\/doi.org\/10.1155\/2014\/307872 (Epub 2014 Nov 23. PMID: 25506447; PMCID: PMC4258922)","journal-title":"Case Rep Neurol Med."},{"issue":"3","key":"10910_CR27","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.jocn.2014.08.016","volume":"22","author":"Z Calic","year":"2015","unstructured":"Calic Z, Cappelen-Smith C, Hodgkinson SJ, McDougall A, Cuganesan R, Brew BJ (2015) Treatment of progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome with intravenous immunoglobulin in a patient with multiple sclerosis treated with fingolimod after discontinuation of natalizumab. J Clin Neurosci 22(3):598\u2013600. https:\/\/doi.org\/10.1016\/j.jocn.2014.08.016 (Epub 2014 Dec 15 PMID: 25523125)","journal-title":"J Clin Neurosci"},{"issue":"6","key":"10910_CR28","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1002\/ana.20703","volume":"58","author":"CH Polman","year":"2005","unstructured":"Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, Lublin FD, Metz LM, McFarland HF, O\u2019Connor PW, Sandberg-Wollheim M, Thompson AJ, Weinshenker BG, Wolinsky JS (2005) Diagnostic criteria for multiple sclerosis: 2005 revisions to the \u201cMcDonald Criteria.\u201d Ann Neurol 58(6):840\u2013846. https:\/\/doi.org\/10.1002\/ana.20703 (PMID: 16283615)","journal-title":"Ann Neurol"},{"issue":"2","key":"10910_CR29","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1002\/ana.22366","volume":"69","author":"CH Polman","year":"2011","unstructured":"Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O\u2019Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS (2011) Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 69(2):292\u2013302. https:\/\/doi.org\/10.1002\/ana.22366 (PMID:21387374;PMCID:PMC3084507)","journal-title":"Ann Neurol"},{"issue":"2","key":"10910_CR30","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","volume":"17","author":"AJ Thompson","year":"2018","unstructured":"Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, Correale J, Fazekas F, Filippi M, Freedman MS, Fujihara K, Galetta SL, Hartung HP, Kappos L, Lublin FD, Marrie RA, Miller AE, Miller DH, Montalban X, Mowry EM, Sorensen PS, Tintor\u00e9 M, Traboulsee AL, Trojano M, Uitdehaag BMJ, Vukusic S, Waubant E, Weinshenker BG, Reingold SC, Cohen JA (2018) Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 17(2):162\u2013173. https:\/\/doi.org\/10.1016\/S1474-4422(17)30470-2 (Epub 2017 Dec 21 PMID: 29275977)","journal-title":"Lancet Neurol"},{"key":"10910_CR31","unstructured":"Joanna Briggs I (2019) The Joanna Briggs Institute critical appraisal tools for use in JBI systematic review: checklists for case reports"},{"issue":"3","key":"10910_CR32","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000559","volume":"6","author":"J Nakahara","year":"2019","unstructured":"Nakahara J, Tomaske L, Kume K, Takata T, Kamada M, Deguchi K, Kufukihara K, Schneider R, Gold R, Ayzenberg I (2019) Three cases of non-carryover fingolimod-PML: Is the risk in Japan increased? Neurol Neuroimmunol Neuroinflamm 6(3):e559. https:\/\/doi.org\/10.1212\/NXI.0000000000000559 (PMID: 31044147; PMCID: PMC6467684)","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"20","key":"10910_CR33","doi-asserted-by":"publisher","first-page":"101","DOI":"10.12659\/AJCR.911521","volume":"24","author":"AM AlTahan","year":"2019","unstructured":"AlTahan AM, Berger T, AlOrainy IA, AlTahan H (2019) Progressive multifocal leukoencephalopathy in the absence of typical radiological changes: can we make a diagnosis? Am J Case Rep 24(20):101\u2013105. https:\/\/doi.org\/10.12659\/AJCR.911521 (PMID: 30674865; PMCID: PMC6354725)","journal-title":"Am J Case Rep"},{"key":"10910_CR34","unstructured":"Clifford DB, Gass A, Richert N, Tornatore C, Vermersch P, Hughes R, Koendgen H, Gold R (2019) Cases reported as progressive multifocal leukoencephalopathy in Ocrelizumab-treated patients with multiple sclerosis. Proceedings of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Stockholm, Sweden"},{"issue":"1","key":"10910_CR35","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000415","volume":"5","author":"S Nishiyama","year":"2017","unstructured":"Nishiyama S, Misu T, Shishido-Hara Y, Nakamichi K, Saijo M, Takai Y, Takei K, Yamamoto N, Kuroda H, Saito R, Watanabe M, Tominaga T, Nakashima I, Fujihara K, Aoki M (2017) Fingolimod-associated PML with mild IRIS in MS: a clinicopathologic study. Neurol Neuroimmunol Neuroinflamm 5(1):e415. https:\/\/doi.org\/10.1212\/NXI.0000000000000415 (PMID: 29725611; PMCID: PMC5930970)","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"19","key":"10910_CR36","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1212\/WNL.0000000000002654","volume":"86","author":"TV Gyang","year":"2016","unstructured":"Gyang TV, Hamel J, Goodman AD, Gross RA, Samkoff L (2016) Fingolimod-associated PML in a patient with prior immunosuppression. Neurology 86(19):1843\u20131845. https:\/\/doi.org\/10.1212\/WNL.0000000000002654 (Epub 2016 Apr 13. PMID: 27164718; PMCID: PMC4862251)","journal-title":"Neurology"},{"issue":"1","key":"10910_CR37","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1186\/s12883-019-1407-2","volume":"19","author":"T Sinnecker","year":"2019","unstructured":"Sinnecker T, Hadisurya J, Schneider-Hohendorf T, Schwab N, Wrede K, Gembruch O, Gold R, Hellwig K, Pilgram-Pastor S, Adams O, Albrecht P, Hartung HP, Aktas O, Kraemer M (2019) Extensive immune reconstitution inflammatory syndrome in Fingolimod-associated PML: a case report with 7 Tesla MRI data. BMC Neurol 19(1):190. https:\/\/doi.org\/10.1186\/s12883-019-1407-2 (PMID: 31399069; PMCID: PMC6688281)","journal-title":"BMC Neurol"},{"issue":"12","key":"10910_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.561158","volume":"3","author":"F Maass","year":"2021","unstructured":"Maass F, von Gottberg P, Franz J, Stadelmann C, B\u00e4hr M, Weber MS (2021) Case report: findings suggestive of paraclinical progressive multifocal leukoencephalopathy and lung cancer-derived brain metastases in an MS patient treated with fingolimod. Front Neurol 3(12):561158. https:\/\/doi.org\/10.3389\/fneur.2021.561158 (PMID: 33613428; PMCID: PMC7886972)","journal-title":"Front Neurol"},{"key":"10910_CR39","doi-asserted-by":"publisher","unstructured":"Boudot de la Motte M, Louapre C, Bertrand A, Reach P, Lubetzki C, Papeix C, Maillart E (2017) Extensive white matter lesions after 2\u2009years of fingolimod: progressive multifocal leukoencephalopathy or MS relapse? Mult Scler 23(4):614\u2013616. https:\/\/doi.org\/10.1177\/1352458516682858. Epub 2016 Dec 14. PMID: 28273764","DOI":"10.1177\/1352458516682858"},{"issue":"1","key":"10910_CR40","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000927","volume":"8","author":"B Fischer-Barnicol","year":"2020","unstructured":"Fischer-Barnicol B, Oechtering J, Kuhle J, Lorscheider J, Kappos L, Derfuss T (2020) Combination of teriflunomide and interferon as follow-up therapy after fingolimod-associated PML. Neurol Neuroimmunol Neuroinflamm 8(1):e927. https:\/\/doi.org\/10.1212\/NXI.0000000000000927 (PMID: 33272956; PMCID: PMC7803336)","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10910_CR41","unstructured":"Barritt A, Das E, Morley N, Seymour M, Saha R, Vera J, Vundavalli S, Dizdarevic S, Nicholas R, Berger J, Fisniku L (2020) Novel treatment approach for fingolimod-associated progressive multifocal leukoencephalopathy in a patient with relapsing remitting multiple sclerosis. InMultiple Sclerosis Journal"},{"key":"10910_CR42","unstructured":"US Food and Drug Administration (2015) FDA Drug safety communication, 08-04-2015. Silver Spring, MD: US Food and Drug Administration. Available from: http:\/\/www.fda.gov\/downloads\/Drugs\/DrugSafety\/UCM457120.pdf. Accessed 24 Oct 2015"},{"issue":"1","key":"10910_CR43","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1186\/s12974-020-01865-7","volume":"17","author":"M Watanabe","year":"2020","unstructured":"Watanabe M, Nakamura Y, Isobe N, Tanaka M, Sakoda A, Hayashi F, Kawano Y, Yamasaki R, Matsushita T, Kira JI (2020) Two susceptible HLA-DRB1 alleles for multiple sclerosis differentially regulate anti-JC virus antibody serostatus along with fingolimod. J Neuroinflammation 17(1):206. https:\/\/doi.org\/10.1186\/s12974-020-01865-7 (PMID: 32646493; PMCID: PMC7350631)","journal-title":"J Neuroinflammation"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-021-10910-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-021-10910-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-021-10910-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,18]],"date-time":"2022-02-18T07:33:40Z","timestamp":1645169620000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-021-10910-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,20]]},"references-count":43,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["10910"],"URL":"https:\/\/doi.org\/10.1007\/s00415-021-10910-1","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,20]]},"assertion":[{"value":"4 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Disclosures: Shitiz Sriwastava, Samiksha Kayastha, Durgesh Chaudhary, Katherine Beard, Syed Hassan Khalid, Xue Bai, Sijin Wen\u2014Reports no disclosure. In the last 2\u00a0years Dr. Lisak has participated as a speaker in meetings sponsored by and received consulting fees and\/or grant support from: Alexion, Argenx, UCB\/Ra Pharmaceuticals, Novartis, Mallinckrodt, Genentech\/Roche, Chugai, Janssen, GLG Consulting, Alpha Sites Consulting, Schlesinger Group Consulting, Slingshot Consulting, Health Sources, Adivo Associates, Smart Analyst, Clairview, Clarion and Decision Resources. He served as Chair of the Adjudication Committee for a MS clinical trial for MedDay (Biotin study). He is funded by a R21 grant by NINDS \u201cMolecular Characterization of B Cell Exosomes in Multiple Sclerosis\u201d and as site PI for NINDS funded study \u201cLP4\/Agrin Antibodies in Double Seronegative Myasthenia Gravis\u201d. He has received publication royalties from Oxford University Press (Neuroimmunology, 2019) and Blackwell Wiley (International Neurology, 2<sup>nd<\/sup> Edition, 2016).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}